DUPONT CONSOLIDATING BIOMEDICAL RESEARCH AT NEW $12 MIL. LAB in Billerica, Massachusetts, the company announced July 10. The 137,000-square-foot basic research facility will house about 120 research scientists and technicians, who formerly were spread out between various DuPont facilities, a spokesman said. The center will be fully operational by early fall. The opening of the new lab coincides with the formal integration of DuPont's NEN Products business into the company's biomedical department. Formerly known as New England Nuclear, NEN had been operating as a wholly owned DuPont subsidiary since its acquisition in 1981, the spokesman explained. NEN primarily manufactures radiopharmaceuticals and radioactive chemicals used in biomedical research. Research at the Billerica facility will focus on "basic research in biotechnology, with emphasis on the diagnosis of infectious diseases, cancer and other medical conditions," DuPont said. The laboratory reaffirms DuPont's "continued growth into the health sciences field," DuPont Vice Chairman Richard Heckert commented. DuPont also recently opened two new health sciences research facilities in Glasgow, Delaware, he said, and plans to dedicate an $85 mil. life sciences research center near Wilmington, Delaware in September.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.
Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
